Sight Sciences (SGHT) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Sight Sciences is set to release its Q2 2025 earnings results on August 7th, with expectations of reporting a net loss of ($0.25) per share and revenue around $18.18 million.
• The company has struggled financially, reporting a negative net margin of 63.24% and a return on equity of -54.62% for the last quarter.
• Recent analyst ratings show a consensus "Hold" rating with an average target price of $3.93, indicating mixed sentiments towards the stock's future performance.

Sight Sciences (NASDAQ:SGHT - Get Free Report) is projected to announce its Q2 2025 earnings results after the market closes on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.25) per share and revenue of $18.18 million for the quarter. Sight Sciences has set its FY 2025 guidance at EPS.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.29) by $0.01. Sight Sciences had a negative return on equity of 54.62% and a negative net margin of 63.24%. The business had revenue of $17.51 million during the quarter, compared to analyst estimates of $16.51 million. On average, analysts expect Sight Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Sight Sciences Stock Down 1.8%

Sight Sciences stock traded down $0.06 during midday trading on Friday, reaching $3.27. The stock had a trading volume of 229,807 shares, compared to its average volume of 112,255. Sight Sciences has a 12 month low of $2.03 and a 12 month high of $7.12. The company has a market capitalization of $169.06 million, a P/E ratio of -3.34 and a beta of 2.45. The company has a fifty day moving average price of $3.83 and a two-hundred day moving average price of $3.14. The company has a current ratio of 10.47, a quick ratio of 9.99 and a debt-to-equity ratio of 0.51.

Analyst Ratings Changes

Several brokerages have recently commented on SGHT. Lake Street Capital increased their price objective on Sight Sciences from $2.50 to $3.00 and gave the stock a "hold" rating in a research note on Friday, May 9th. Morgan Stanley increased their price objective on Sight Sciences from $3.00 to $4.00 and gave the stock an "equal weight" rating in a research note on Tuesday, July 15th. Wall Street Zen lowered Sight Sciences from a "hold" rating to a "sell" rating in a report on Friday, July 18th. Piper Sandler reaffirmed a "neutral" rating and issued a $4.00 target price (up from $3.50) on shares of Sight Sciences in a report on Wednesday, June 18th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Sight Sciences in a report on Wednesday, April 9th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $3.93.

Insider Buying and Selling

In related news, insider Jeremy B. Hayden sold 9,160 shares of Sight Sciences stock in a transaction on Thursday, July 3rd. The shares were sold at an average price of $4.17, for a total transaction of $38,197.20. Following the transaction, the insider owned 266,321 shares in the company, valued at approximately $1,110,558.57. The trade was a 3.33% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Paul Badawi sold 23,637 shares of the business's stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $4.15, for a total transaction of $98,093.55. Following the completion of the sale, the chief executive officer owned 5,986,943 shares in the company, valued at approximately $24,845,813.45. The trade was a 0.39% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 43,365 shares of company stock valued at $180,017. 30.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Sight Sciences

Several hedge funds have recently added to or reduced their stakes in the company. Strs Ohio purchased a new stake in Sight Sciences during the first quarter valued at approximately $158,000. AQR Capital Management LLC purchased a new position in shares of Sight Sciences in the first quarter worth $128,000. Finally, Rhumbline Advisers raised its holdings in shares of Sight Sciences by 9.5% in the first quarter. Rhumbline Advisers now owns 49,797 shares of the company's stock worth $120,000 after buying an additional 4,319 shares during the last quarter. 55.51% of the stock is currently owned by institutional investors.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.